News
Neurologist Dr. Leah Croll talks about the new research suggesting they might help in treating people with alcohol use ...
First-generation GLP-1 weight-loss drugs can help reduce the risk of obesity-related cancers, new research shows. Liraglutide ...
Zepbound — the brand name for tirzepatide — is the most effective GLP-1 medication for weight loss, according to one study.
However, it is important to note that the study's cross-sectional design means these findings are correlational, not causal; the data do not show that these factors cause interest in GLP-1 use.
Children who are living with severe obesity are more likely to experience a clinically relevant change in BMI when GLP-1 ...
22h
News Medical on MSNGLP-1 drugs linked to significant BMI reduction in children with severe obesityChildren who are living with severe obesity are more likely to experience a clinically relevant change in BMI when GLP-1 agonist drugs form part of their treatment, new research being presented at ...
Study presented at DDW ... trial design to support drug development. The study titled, "A Genetic Risk Score Associated with Nausea Resulting from GLP-1 Agonist Treatment: A Post-Hoc Analysis ...
Share on Pinterest Research is looking for ways to minimize muscle loss from GLP-1 drugs taken to treat ... said that “this study was helpful to show that some muscle can occur with significant ...
The phase 2 ELAD study of Novo Nordisk's once-daily injectable GLP-1 agonist liraglutide in people with early-stage Alzheimer's has shown that the drug was able to reduce shrinking in the areas of ...
GLP-1 drugs fueled a jump in R.I. health care spending, nearly tripling in three years, report finds
The diabetes and weight loss drugs are “not cost-effective at their current prices, and are largely unavailable to people with lower incomes,” the report said.
GLP-1 drugs have helped ... on proper medication use, resistance training, and adequate protein intake. Body composition was measured at the start of the study, at three months, and again at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results